Table 2.
Registered active drug trials in osteoarthritis
| Study type and number of participants | Drug | Target or drug type | Route | Trial status | Primary outcome | Secondary outcomes | |
|---|---|---|---|---|---|---|---|
| NCT04456686 | Phase 2 randomised controlled trial; 125 participants | LY3016859 | Transforming growth factor α and epiregulin | Intravenous | Recruiting | Pain (numeric rating scale) | Function |
| NCT04447898 | Phase 1 randomised controlled trial; 24 participants | PPV-06 vaccination | Interleukin-6 | Subcutaneous | Not yet recruiting | Safety | Not given |
| NCT04385303 | Phase 3 randomised controlled trial; 726 participants | Lorecivivint (SM04690) | Wnt pathway | Intra-articular | Recruiting | Pain (numeric rating scale) | Function |
| NCT03928184 | Phase 3 randomised controlled trial; 725 participants | Lorecivivint (SM04690) | Wnt pathway | Intra-articular | Recruiting | Pain (numeric rating scale) | Function; structure |
| NCT04318041 | Phase 3 randomised controlled trial; 128 participants | Diacerin | Unknown or anti-inflammatory | Oral | Not yet recruiting | Structure (MRI) | Function |
| NCT04303026 | Phase 3 randomised controlled trial; 70 participants | Zoledronic acid | Osteoclast activity | Intravenous | Recruiting | Pain (Visual analogue scale) | Function; structure |
| NCT04231318 | Phase 3 randomised controlled trial; 231 participants | Cingal | Triamcinalone plus hyaluronate | Intra-articular | Not yet recruiting | Pain (WOMAC) | Not given |
| NCT04224584 | Phase 2 crossover controlled trial; 40 participants | Duloxetine | CNS reuptake inhibitor | Oral | Recruiting | Pressure pain threshold | Not given |
| NCT04117893 | Phase 4 randomised open-label trial; 150 participants | Duloxetine plus hyaluronic acid plus triamcinolone | CNS reuptake inhibitor plus corticosteroid plus hyaluronan | Oral and intra-articular | Not yet recruiting | Pain (average pain scores) | Function |
| NCT04261049 | Open-label trial; 35 participants | Zilretta | Corticosteroid (slow release) | Intra-articular | Not yet recruiting | Muscle strength; function and gait | Not given |
| NCT04123561 | Phase 3 randomised controlled trial; 500 participants | TLC599 | Corticosteroid (slow release) | Intra-articular | Recruiting | Pain (WOMAC) | Function |
| NCT04120402 | Phase 2 randomised controlled trial; 238 participants | EP-104IAR | Corticosteroid (slow release) | Intra-articular | Not yet recruiting | Pain (WOMAC) | Function |
| NCT04097379 | Phase 2 randomised controlled trial; 40 participants | LRX712 | Not disclosed; pro-regenerative | Intra-articular | Not yet recruiting | Structure (sodium cartilage content by MRI) | Pharmaco-kinetics |
| NCT03913442 | Phase 4 randomised controlled trial; 120 participants | Colchicine | Anti-inflammatory; precise mechanism disputed | Oral | Recruiting | Pain (visual analogue scale) | Function |
| NCT03815448 | Randomised controlled trial; 200 participants | Methotrexate | Immunosuppressant (folate antagonist) | Oral | Recruiting | Synovitis (MRI); pain (visual analogue scale) | Function |
| NCT01927484 | Randomised controlled trial; 120 participants | Methotrexate | Immunosuppressant (folate antagonist) | Oral | Not yet recruiting* | Pain (visual analogue scale) | Function |
| NCT02905799 | Phase 3 randomised controlled trial; 164 participants | Resveratrol | Anti-ageing or anti-inflammatory (multiple proposed mechanisms of action) | Oral | Recruiting | Pain (numeric rating scale) | Function |
| NCT04119687 | Phase 1 open-label trial; 24 participants | FX201 | Interleukin-1 receptor antagonist gene therapy | Intra-articular | Recruiting | Safety | Biodistribution |
| NCT02790723 | Phase 1 open label; 9 participants | Sc-rAAV2.5IL-1Ra | Interleukin-1 receptor antagonist gene therapy | Intra-articular | Recruiting | Safety | Not given |
| NCT02471118 | Phase 2 crossover randomised controlled trial; 100 participants | Adalimumab | Anti-tumour necrosis factor | Subcutaneous | Recruiting | OARSI/OMERACT response | Pain; function |
| NCT03595618 | Phase 2 randomised controlled trial; 928 participants | GLPG1972 | ADAMTS-5 inhibitor | Oral | Not yet recruiting | Structure (cartilage thickness by MRI) | Other structure; function and pain |
Data taken from ClinicalTrials.gov on July 24, 2020.
*
Trial terminated due to COVID-19.